Literature DB >> 28064069

Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice.

Ajay Amit1, Manas R Dikhit2, Ashish Kumar Singh3, Vikash Kumar1, Shashi S Suman4, Ashu Singh5, Akhilesh Kumar1, Ajit Kumar Thakur6, Vidyanand Ravi Das7, Pradeep Das8, Sanjiva Bimal9.   

Abstract

In the present study, the efficacy of Leishmania donovani protein disulfide isomerase (LdPDI) as a DNA vaccine was evaluated in BALB/C mice. Mice immunized with the LdPDI-DNA construct were found to be the most immuno-reactive, as the construct induced higher T-cell proliferation. The increased T-cell proliferation was associated with a substantial rise in Th1 and Th17+ CD4 cell response and triggered a higher proportion of CD8+ T cells for the release of interferon-gamma along with a reduced splenic parasite load on Days20 and 60 post challenge (PC). Furthermore, the vaccine construct triggered increased interferon (IFN)-γ, interleukin(IL)-17A, and IL-22 release accompanied by decreased extracellular signal-regulated kinases (ERK) 1/2 signaling and increased mitogen-activated protein kinase (MAPK) signaling coinciding with an increase in the amount of nitrite and reactive oxygen species (ROS)in vaccinating the splenocyts. We summarize from our data that the PDI-DNA construct of Leishmania donovani has the potential to elicit protective immunity through the pro-inflammatory cytokines of CD8+ and CD4+(Th1 and Th17) following an intervention in the downstream signaling event of ERK1/2 (probably through p38MAPK signaling). Therefore, the study suggests a new control against visceral leishmaniasis in the future.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA vaccine; Interferon gamma; Interleukin (IL)-17A; Mitogen-activated protein kinase (MAPK); Nitric oxide; Protein disulfide isomerase (PDI); Visceral leishmaniasis

Mesh:

Substances:

Year:  2017        PMID: 28064069     DOI: 10.1016/j.molimm.2016.12.022

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  12 in total

1.  An immunoproteomic approach to identifying immunoreactive proteins in Leishmania infantum amastigotes using sera of dogs infected with canine visceral leishmaniasis.

Authors:  Sajad Rashidi; Zahra Mojtahedi; Bahador Shahriari; Kurosh Kalantar; Ghasem Ghalamfarsa; Mehdi Mohebali; Gholamreza Hatam
Journal:  Pathog Glob Health       Date:  2019-05-17       Impact factor: 2.894

Review 2.  Cytokines and Signaling Networks Regulating Disease Outcomes in Leishmaniasis.

Authors:  Amrita Saha; Souravi Roy; Anindita Ukil
Journal:  Infect Immun       Date:  2022-07-11       Impact factor: 3.609

3.  DNA prime-protein boost vaccine encoding HLA-A2, HLA-A24 and HLA-DR1 restricted epitopes of CaNA2 against visceral leishmaniasis.

Authors:  Jinlei He; Fan Huang; Jianhui Zhang; Han Chen; Qiwei Chen; Junrong Zhang; Jiao Li; Zhiwan Zheng; Dali Chen; Jianping Chen
Journal:  Immunology       Date:  2018-10-24       Impact factor: 7.397

4.  Human Interleukin-32γ Plays a Protective Role in an Experimental Model of Visceral Leishmaniasis in Mice.

Authors:  Leo A B Joosten; Fátima Ribeiro-Dias; Rodrigo Saar Gomes; Muriel Vilela Teodoro Silva; Jéssica Cristina Dos Santos; Christine van Linge; Juliana Machado Reis; Mauro Martins Teixeira; Sebastião Alves Pinto; Miriam Leandro Dorta; Xiyuan Bai; Edward D Chan; Charles A Dinarello; Milton Adriano Pelli Oliveira
Journal:  Infect Immun       Date:  2018-04-23       Impact factor: 3.441

5.  Identification of Potential MHC Class-II-Restricted Epitopes Derived from Leishmania donovani Antigens by Reverse Vaccinology and Evaluation of Their CD4+ T-Cell Responsiveness against Visceral Leishmaniasis.

Authors:  Manas Ranjan Dikhit; Akhilesh Kumar; Sushmita Das; Budheswar Dehury; Ajaya Kumar Rout; Fauzia Jamal; Ganesh Chandra Sahoo; Roshan Kamal Topno; Krishna Pandey; V N R Das; Sanjiva Bimal; Pradeep Das
Journal:  Front Immunol       Date:  2017-12-14       Impact factor: 7.561

6.  Conversion of asymptomatic infection to symptomatic visceral leishmaniasis: A study of possible immunological markers.

Authors:  Vidya Nand Rabi Das; Sanjiva Bimal; Niyamat Ali Siddiqui; Ashish Kumar; Krishna Pandey; Sanjay Kumar Sinha; Roshan Kamal Topno; Vijay Mahentesh; Ashish Kumar Singh; Chandra Shekhar Lal; Subhankar Kumar Singh; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2020-06-18

7.  PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.

Authors:  Hao Zhang; Jialin He; Ziyu Dai; Zeyu Wang; Xisong Liang; Fengqiong He; Zhiwei Xia; Songshan Feng; Hui Cao; Liyang Zhang; Quan Cheng
Journal:  Front Immunol       Date:  2021-02-16       Impact factor: 7.561

8.  A computer-aided approach to identify novel Leishmania major protein disulfide isomerase inhibitors for treatment of leishmaniasis.

Authors:  Noureddine Ben Khalaf; Susie Pham; Giuseppe Romeo; Sara Abdelghany; Sebastiano Intagliata; Peter Sedillo; Loredana Salerno; Jessica Gonzales; Dahmani M Fathallah; Douglas J Perkins; Ivy Hurwitz; Valeria Pittalà
Journal:  J Comput Aided Mol Des       Date:  2021-02-22       Impact factor: 3.686

9.  The potential HLA Class I-restricted epitopes derived from LeIF and TSA of Leishmania donovani evoke anti-leishmania CD8+ T lymphocyte response.

Authors:  Manas Ranjan Dikhit; Sushmita Das; Vijaya Mahantesh; Akhilesh Kumar; Ashish Kumar Singh; Budheswar Dehury; Ajaya Kumar Rout; Vahab Ali; Ganesh Chandra Sahoo; Roshan Kamal Topno; Krishna Pandey; V N R Das; Sanjiva Bimal; Pradeep Das
Journal:  Sci Rep       Date:  2018-09-21       Impact factor: 4.379

10.  A Vaccine Based on Kunitz-Type Molecule Confers Protection Against Fasciola hepatica Challenge by Inducing IFN-γ and Antibody Immune Responses Through IL-17A Production.

Authors:  Leonardo Silvane; Daiana Pamela Celias; Pablo Alberto Romagnoli; Belkys Angélica Maletto; María Fernanda Sanchez Vallecillo; Laura Silvina Chiapello; Santiago Daniel Palma; Daniel Alberto Allemandi; Rodrigo Eduardo Fabrizio Sanabria; César Iván Pruzzo; Claudia Cristina Motrán; Laura Cervi
Journal:  Front Immunol       Date:  2020-10-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.